Clinical trial · no report yet · Phase 2
NCT06100874
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
- NCT06100874 ↗
- Active not recruiting
- Adrienne G. Waks
- 37 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 30 | |
| YouTube | 4 | |
| X videos | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Her 2 Positive Breast Cancer; Breast Cancer Female; Breast Cancer Metastatic
- Interventions
- Sacituzumab Govitecan; Trastuzumab; Trastuzumab and Hyaluronidase-oysk
- Arms
- Sacituzumab Govitecan + Trastuzumab (or Biosimilar) · Experimental
- Enrollment
- 28
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Adrienne G. Waks with Gilead Sciences
- Start
- Nov 20, 2023
- Primary completion
- Feb 9, 2026
- Results posted
- No
- Registry record
- NCT06100874 · updated Feb 24, 2026